Technical Analysis for GTHX - G1 Therapeutics, Inc.

Grade Last Price % Change Price Change
D 20.43 0.59% 0.12
GTHX closed up 0.59 percent on Friday, March 5, 2021, on 1.18 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical GTHX trend table...

Date Alert Name Type % Chg
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Multiple of Ten Bullish Other 0.59%
Wide Bands Range Expansion 0.59%
Lower Bollinger Band Touch Weakness 0.59%
Oversold Stochastic Weakness 0.59%
Fell Below 50 DMA Bearish -6.46%
180 Bearish Setup Bearish Swing Setup -6.46%
Wide Bands Range Expansion -6.46%
Older End-of-Day Signals for GTHX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Treatment Of Cancer Breast Cancer Treatment Of Breast Cancer Hormones Her2 Her2/Neu Estrogen Protein Kinase Inhibitors Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Fulvestrant

Is GTHX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 37.0687
52 Week Low 8.8
Average Volume 1,571,605
200-Day Moving Average 18.07
50-Day Moving Average 22.95
20-Day Moving Average 25.99
10-Day Moving Average 22.92
Average True Range 2.21
ADX 32.14
+DI 14.30
-DI 28.65
Chandelier Exit (Long, 3 ATRs ) 30.43
Chandelier Exit (Short, 3 ATRs ) 25.53
Upper Bollinger Band 33.22
Lower Bollinger Band 18.75
Percent B (%b) 0.12
BandWidth 55.67
MACD Line -0.81
MACD Signal Line 0.15
MACD Histogram -0.9625
Fundamentals Value
Market Cap 777.28 Million
Num Shares 38 Million
EPS -2.70
Price-to-Earnings (P/E) Ratio -7.56
Price-to-Sales 18.79
Price-to-Book 2.76
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.17
Resistance 3 (R3) 24.07 22.73 23.54
Resistance 2 (R2) 22.73 21.78 22.78 23.33
Resistance 1 (R1) 21.58 21.19 20.91 21.68 23.13
Pivot Point 20.24 20.24 19.91 20.29 20.24
Support 1 (S1) 19.09 19.29 18.42 19.19 17.73
Support 2 (S2) 17.75 18.70 17.80 17.53
Support 3 (S3) 16.60 17.75 17.32
Support 4 (S4) 16.70